cannabis products
  • Tilray Brands’ (TLRY) medical cannabis division, Tilray Medical, has received approval to commercialize its medical cannabis products in Poland
  • The approval allows Tilray Medical to expand its product offering and distribution across pharmacies in Europe
  • In Poland, Tilray Medical has established multiple partnerships with pharmaceutical companies to distribute both Tilray branded and unbranded medical cannabis products
  • Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis
  • Tilray Stock (TSX:TLRY) is up 1.30 per cent, trading at C$5.46 per share at 1:04 pm ET

Tilray Brands’ (TLRY) medical cannabis division, Tilray Medical, has received approval to commercialize its medical cannabis products in Poland.

The approval allows Tilray Medical to expand its product offering and distribution across pharmacies in Europe.

Denise Faltischek, Chief Strategy Officer and Head of International Business of Tilray commented on the news.

“I’m extremely proud of our team for once again expanding our approved authorization for Tilray Medical products across Europe. Tilray will continue to advocate for reasonable patient access to reliable and high-quality medical cannabis in Europe and countries around the world.”

Tilray Medical is a leading international provider of EU-GMP certified medical cannabis products in 21 countries. It has a comprehensive portfolio of trusted and reliable THC and CBD products each with a unique profile of cannabinoids and terpenes. 

Tilray Medical has established multiple partnerships with pharmaceutical companies in Poland to distribute Tilray branded and unbranded medical cannabis products. Patients may obtain prescriptions for medical cannabis in Poland through their preferred medical doctor.

Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. Tilray Medical is one of the biggest suppliers of medical cannabis brands to patients, physicians, hospitals, pharmacies, researchers, and governments, in 21 countries and across five continents.


More From The Market Online

The Market Online’s Weekly Cannabis Report – April 19, 2024

Cannabis news this week: Canopy Growth shareholders overwhelmingly voted to approve a new class of exchangeable shares.

Buzz on the Bullboards: Challenges amid inflation and geopolitical tensions

Canadian and U.S. stock markets grapple with a host of challenges, from surging inflation data to escalating tensions in the Middle East.

Xebra Brands receives second CBD approval by Mexican authority

Xebra Brands (CSE:XBRA) announces it has received its second COFEPRIS approval for CBD product authorization in Mexico.
Canopy Growth - CEO, David Klein.

Canopy Growth shareholders approve Canopy USA asset strategy

After rearranging its capital structure, Canopy Growth (TSX:WEED) will be closer to establishing a U.S.-based multi-state operator.